Residuals and Outliers in Replicate Design Crossover Studies [BE/BA News]

posted by d_labes  – Berlin, Germany, 2011-04-04 10:53 (4327 d 13:05 ago) – Posting: # 6855
Views: 32,343

Dear Helmut, dear All!

FYI:

Robert Schall, Laszlo Endrenyi, Arne Ring
Residuals and Outliers in Replicate Design Crossover Studies
Journal of Biopharmaceutical Statistics, 20: 4, 835 — 849

Online accessible here as preprint or here.

IMHO this fits excellent into the framework of scaled ABE evaluated via suitable intra-subject contrasts as outlined in the Progesterone guidance :ok:.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
26 visitors (0 registered, 26 guests [including 11 identified bots]).
Forum time: 22:59 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5